# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst David Saxon reiterates ZimVie (NASDAQ:ZIMV) with a Hold.
U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday.
Outlook for ZimVieAs previously communicated, ZimVie expects to achieve an annualized financial profile of $455+ million in Net...
ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced that it has closed the previousl...
Barclays analyst Matt Miksic maintains ZimVie (NASDAQ:ZIMV) with a Underweight and raises the price target from $13 to $16.
Management raises financial targets for continuing operations for the 12 month period post-spine sale: Net Sales $455M+, Adjust...
ZimVie (NASDAQ:ZIMV) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.12 by 16....
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...